CO2018004132A2 - Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer - Google Patents

Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer

Info

Publication number
CO2018004132A2
CO2018004132A2 CONC2018/0004132A CO2018004132A CO2018004132A2 CO 2018004132 A2 CO2018004132 A2 CO 2018004132A2 CO 2018004132 A CO2018004132 A CO 2018004132A CO 2018004132 A2 CO2018004132 A2 CO 2018004132A2
Authority
CO
Colombia
Prior art keywords
extracellular domain
cancer treatment
domain polypeptides
polypeptides
ecd
Prior art date
Application number
CONC2018/0004132A
Other languages
English (en)
Inventor
Thomas Brennan
David Bellovin
David Busha
Barbara Sennino
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of CO2018004132A2 publication Critical patent/CO2018004132A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud hace referencia a polipéptidos del dominio extracelular (ECD) de la CD80 (B7-1) y moléculas de fusión al ECD de la CD80 y su uso en el tratamiento del cáncer, tanto solos como en combinación con otros agentes terapéuticos, tales como agentes que estimulan el sistema inmunitario tales como inhibidores de PD-1/PD-L1.
CONC2018/0004132A 2015-11-02 2018-04-18 Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer CO2018004132A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562249836P 2015-11-02 2015-11-02
US201662373654P 2016-08-11 2016-08-11
PCT/US2016/059838 WO2017079117A1 (en) 2015-11-02 2016-11-01 Cd80 extracellular domain polypeptides and their use in cancer treatment

Publications (1)

Publication Number Publication Date
CO2018004132A2 true CO2018004132A2 (es) 2018-11-30

Family

ID=57286882

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0004132A CO2018004132A2 (es) 2015-11-02 2018-04-18 Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer

Country Status (21)

Country Link
US (4) US10273281B2 (es)
EP (1) EP3371208A1 (es)
JP (1) JP6936221B2 (es)
KR (1) KR20180069903A (es)
CN (1) CN108884139A (es)
AU (1) AU2016350701B2 (es)
BR (1) BR112018008865A8 (es)
CA (1) CA3001131A1 (es)
CL (2) CL2018001172A1 (es)
CO (1) CO2018004132A2 (es)
CR (1) CR20180306A (es)
EA (1) EA201891106A1 (es)
EC (1) ECSP18041501A (es)
IL (1) IL258725A (es)
MA (1) MA43163A (es)
MX (1) MX2018005517A (es)
PE (1) PE20181300A1 (es)
PH (1) PH12018500933A1 (es)
SG (1) SG11201803009VA (es)
TW (1) TW201722985A (es)
WO (1) WO2017079117A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
WO2016168771A2 (en) 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
JP6807385B2 (ja) 2015-11-02 2021-01-06 ブループリント メディシンズ コーポレイション Ｒｅｔの阻害剤
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
BR112019018747A2 (pt) 2017-03-16 2020-05-05 Alpine Immune Sciences Inc proteínas imunomoduladoras variantes de cd80 e usos das mesmas
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019073080A1 (en) * 2017-10-13 2019-04-18 Ose Immunotherapeutics ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF
EA202091810A1 (ru) 2018-03-02 2021-01-29 Файв Прайм Терапьютикс, Инк. Антитела к b7-h4 и способы их применения
CA3096043A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
CN112543642A (zh) * 2018-08-29 2021-03-23 戊瑞治疗有限公司 CD80胞外结构域Fc融合蛋白给药方案
BR112020015030A2 (pt) * 2018-09-17 2021-03-16 Gi Innovation, Inc. Proteína de fusão compreendendo a proteína il-2 e a proteína cd80 e uso da mesma
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
WO2020172482A2 (en) 2019-02-22 2020-08-27 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors
WO2020214928A1 (en) 2019-04-18 2020-10-22 Five Prime Therapeutics, Inc. Bioassay for t-cell co-stimulatory proteins containing fc domains
US11788072B2 (en) * 2019-04-30 2023-10-17 Innovative Cellular Therapeutics Holdings, Ltd. Activation of APC in immunotherapy
EP3963079A1 (en) 2019-05-03 2022-03-09 Five Prime Therapeutics, Inc. Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins
CN114901807B (zh) * 2019-11-20 2023-07-11 吉爱希公司 调节性t细胞培养组合物及其用途
JP2023503098A (ja) * 2019-11-20 2023-01-26 ジーアイ・セル・インコーポレイテッド Ｔ細胞培養用培地組成物及びこれを用いたｔ細胞の培養方法
EP4063491A4 (en) * 2019-11-20 2023-02-01 GI Cell, Inc. COMPOSITION FOR GROWING NATURAL KILLER CELLS AND METHOD OF MAKING NATURAL KILLER CELLS USING THE SAME
CN110732021B (zh) * 2019-11-21 2020-08-25 北京启辰生生物科技有限公司 用于解除肿瘤免疫抑制的组合物及其应用
CN110743006B (zh) * 2019-11-22 2020-08-25 北京启辰生生物科技有限公司 用于协同解除免疫细胞衰竭的组合物及应用
KR20210065874A (ko) * 2019-11-27 2021-06-04 주식회사 지아이셀 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물
WO2021173903A1 (en) * 2020-02-26 2021-09-02 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein therapy
MX2022015261A (es) 2020-06-03 2023-03-14 Boehringer Ingelheim Int Rhabdovirus recombinante que codifica una proteina de fusion fc de dominio extracelular cd80.
KR102373965B1 (ko) * 2020-06-05 2022-03-15 (주)지아이이노베이션 Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
WO2022226170A1 (en) * 2021-04-22 2022-10-27 Cornell University The immunomodulatory ligand b7-1 mediates synaptic remodeling by p75ntr

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US6071716A (en) 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US6130316A (en) 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US5858776A (en) 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
EP0749323B1 (en) 1994-03-08 2000-11-29 Dana-Farber Cancer Institute Methods for modulating t cell anergy
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US6491925B2 (en) 1996-08-15 2002-12-10 Emory University Compositions and methods for cancer prophylaxis and/or treatment
AU8800598A (en) 1997-06-20 1999-01-04 Innogenetics N.V. B7-binding molecules for treating immune diseases
WO2000025803A1 (fr) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Preparations contenant une proteine betacelluline
US7011833B1 (en) 1999-05-06 2006-03-14 Genetics Institute, Inc. Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
US7064111B1 (en) 1999-10-05 2006-06-20 Georgetown University Use of soluble costimulatory factor for tumor immuno-gene therapy
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
AU2002368044A1 (en) 2001-06-22 2004-04-19 Maxygen, Inc. Co-stimulatory molecules
WO2003039486A2 (en) 2001-11-09 2003-05-15 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
MXPA05006828A (es) 2002-12-23 2005-09-08 Wyeth Corp Anticuerpos contra pd-1, y sus usos.
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
PT1638941E (pt) 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
CA2534474C (en) 2003-08-04 2014-09-23 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
WO2006050172A2 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
SI2161336T1 (sl) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
KR101562549B1 (ko) 2005-05-10 2015-10-23 인사이트 홀딩스 코포레이션 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법
CA2614039C (en) * 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
TWI382974B (zh) 2005-12-20 2013-01-21 Incyte Corp 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008037080A1 (en) 2006-09-29 2008-04-03 Universite De Montreal Methods and compositions for immune response modulation and uses thereof
US20100189716A1 (en) 2007-03-28 2010-07-29 Biogen Idec Inc. Treatment of hodgkins lymphoma
JP2010522772A (ja) 2007-03-28 2010-07-08 バイオジェン・アイデック・インコーポレイテッド 腫瘍微小環境の調整
EP2141997B1 (en) 2007-03-30 2012-10-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
CN101358225B (zh) * 2007-07-30 2012-02-01 厦门大学 高唾液酸含量的免疫球蛋白抗体的制备方法与应用
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
ES2399088T3 (es) * 2007-11-01 2013-03-25 Perseid Therapeutics Llc Polipéptidos y ácidos nucleicos inmunosupresores
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
WO2009089149A1 (en) 2008-01-03 2009-07-16 The Johns Hopkins University B7-h1 (cd274) antagonists induce apoptosis of tumor cells
HUE028958T2 (en) * 2008-02-08 2017-01-30 Medimmune Llc Anti-IFNAR1 antibodies with reduced Fc ligand affinity
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
PL3023438T3 (pl) 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
ES2692268T3 (es) 2011-03-29 2018-12-03 Roche Glycart Ag Variantes de Fc de anticuerpo
NO2694640T3 (es) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
KR20140058532A (ko) 2011-06-30 2014-05-14 겐자임 코포레이션 Ｔ-세포 활성화 억제제
BR112013032552A2 (pt) 2011-07-24 2017-12-12 Curetech Ltd variantes de anticorpos monoclonais humanizados imunomoduladores
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
US9567642B2 (en) 2012-02-02 2017-02-14 Massachusetts Institute Of Technology Methods and products related to targeted cancer therapy
EP2809345A4 (en) 2012-02-03 2015-11-25 Univ Emory IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP2934589B1 (en) * 2012-12-18 2021-01-13 The Rockefeller University Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
US20160024179A1 (en) 2013-03-15 2016-01-28 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
EP4356960A2 (en) 2013-03-15 2024-04-24 F. Hoffmann-La Roche AG Biomarkers and methods of treating pd-1 and pd-l1 related conditions
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
US20170044268A1 (en) 2013-12-23 2017-02-16 OncoMed Pharmaceuticals Immunotherapy with Binding Agents
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
DK3309174T3 (da) 2014-07-11 2022-06-07 Ventana Med Syst Inc ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
EP3194440A1 (en) 2014-09-15 2017-07-26 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
US10584157B2 (en) 2015-03-16 2020-03-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Isolated peptides derived from the B7 ligand dimer interface and uses thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2016168771A2 (en) 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
CN108396015B (zh) 2015-04-30 2022-02-18 皮斯奥克斯治疗公司 编码b7蛋白质的溶瘤腺病毒
HUE056201T2 (hu) 2015-07-30 2022-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017042814A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Use of perforin positive immature dendritic cells in disease treatment
AU2016323069A1 (en) 2015-09-14 2018-04-12 Alpine Immune Sciences, Inc. Tunable variant immunoglobulin superfamily domains and engineered cell therapy
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20180107105A (ko) 2015-12-17 2018-10-01 싸이오서스 테라퓨틱스 엘티디. 항-tcr-복합체 항체 또는 단편을 암호화하는 군 b 아데노바이러스
AU2017224843A1 (en) 2016-02-25 2018-08-23 Cell Medica Switzerland Ag Binding members to PD-L1
CA3014458A1 (en) 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP2019507180A (ja) 2016-03-04 2019-03-14 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ がんに対する組合せ療法
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
EP3442999A2 (en) 2016-04-15 2019-02-20 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
JP7421338B2 (ja) 2016-09-27 2024-01-24 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
KR20190099194A (ko) 2016-10-20 2019-08-26 알파인 이뮨 사이언시즈, 인코포레이티드 분비가능한 변이체 면역조절 단백질 및 조작된 세포 치료
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
CN112543642A (zh) 2018-08-29 2021-03-23 戊瑞治疗有限公司 CD80胞外结构域Fc融合蛋白给药方案
WO2020172482A2 (en) 2019-02-22 2020-08-27 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors
EP3963079A1 (en) 2019-05-03 2022-03-09 Five Prime Therapeutics, Inc. Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins

Also Published As

Publication number Publication date
EA201891106A1 (ru) 2018-12-28
MA43163A (fr) 2018-09-12
CL2018001172A1 (es) 2018-09-21
US20170145071A1 (en) 2017-05-25
CL2020003392A1 (es) 2021-07-19
MX2018005517A (es) 2018-11-09
AU2016350701A1 (en) 2018-05-31
SG11201803009VA (en) 2018-05-30
US20190194288A1 (en) 2019-06-27
US20240041979A1 (en) 2024-02-08
BR112018008865A8 (pt) 2019-02-26
US11098103B2 (en) 2021-08-24
BR112018008865A2 (pt) 2018-11-06
JP2018535204A (ja) 2018-11-29
CA3001131A1 (en) 2017-05-11
TW201722985A (zh) 2017-07-01
ECSP18041501A (es) 2018-06-30
CR20180306A (es) 2018-10-16
US20190202889A1 (en) 2019-07-04
AU2016350701B2 (en) 2021-08-19
PE20181300A1 (es) 2018-08-09
WO2017079117A1 (en) 2017-05-11
US10273281B2 (en) 2019-04-30
JP6936221B2 (ja) 2021-09-15
EP3371208A1 (en) 2018-09-12
KR20180069903A (ko) 2018-06-25
IL258725A (en) 2018-06-28
CN108884139A (zh) 2018-11-23
PH12018500933A1 (en) 2018-11-19

Similar Documents

Publication Publication Date Title
CO2018004132A2 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
GT201500248A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
CL2015003271A1 (es) Derivados de ester de moduladores del receptor de andrógeno y métodos para su uso.
DOP2015000058A (es) Derivados tricíclicos de quinolinas y de quinoxalinas
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
GEP20237538B (en) Pd-1-binding molecules and methods of use thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
UY36068A (es) INHIBIDORES DE TGF-ß Y MÉTODOS DE USO
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
MX2019012849A (es) Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
BR112016013116A2 (pt) Inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
BR112015029145A2 (pt) Usos de um domínio extracelular (ecd) de receptor de fator de crescimento de fibroblastos 1 (fgfr1) e métodos de identificação de pacientes
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas